Literature DB >> 9499446

Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: an immunocytochemical study.

E Bajetta1, L Celio, A Di Leo, C Bartoli, S Pilotti, M Leutner, A Bono, L Ferrari, R Buzzoni, N Zilembo, D De Candis, D Moglia.   

Abstract

The effects of the short-term pre-operative administration of tamoxifen (TAM, 20 mg once daily) on the tumor levels of steroid receptors and the nuclear proliferation Ki-67 antigen, were investigated in 32 elderly patients with hormone-sensitive, operable primary breast cancer by means of fine-needle aspiration biopsy (FNAB). The FNAB smears before (pre-TAM) and after six weeks of treatment (post-TAM) were stained immunocytochemically in order to obtain an H-score for steroid receptors, and the percentage of cellular nuclei containing Ki-67. The mean oestrogen receptor (ER) score between the pre- and post-TAM specimens fell from 181.2 9.7 ( SEM) to 148.1 7.9 (Wilcoxon's matched-pairs signed-rank test, p=0. 01) and there was also a significant decrease in both the mean progesterone receptor (PgR) score (178.4 10.6 vs 148.5 10.6; p=0.01) and mean Ki-67 index (8.2% 1.2 vs 4.9% 0.9; p=0.0002). The reliability of FNAB as a sampling method was checked by comparing the results of the immunocytochemical assay (ICA) of the post-TAM biopsies with those of the immunohistochemical assay (IHA) of the corresponding excised tumors. There was a positive correlation between the ICA and IHA scores: ER (Spearman's correlation coefficient, rho=0.66, p<0.001), PgR (rho=0.84, p<0.001) and Ki-67 (rho=0.96, p<0.001). We conclude that the sequential use of FNAB is a reliable means of assessing the behaviour of within-tumor biomarkers during endocrine therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499446     DOI: 10.3892/ijo.12.4.853

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  4 in total

1.  Tailoring therapy for locally advanced breast cancer using molecular profiles: are we there yet?

Authors:  Christopher Fosker; Julian W Adlard; Abeer Shaaban
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

2.  Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.

Authors:  James D Byrne; Mohammad R N Jajja; Allison N Schorzman; Amanda W Keeler; J Christopher Luft; William C Zamboni; Joseph M DeSimone; Jen Jen Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

3.  A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.

Authors:  Linda R Duska; Virginia L Filiaci; Joan L Walker; Laura L Holman; Emily K Hill; Richard G Moore; Kari L Ring; Michael L Pearl; Carolyn Y Muller; Christina L Kushnir; Heather A Lankes; Megan I Samuelson; Kelley S Carrick; Anand Rajan; William H Rodgers; Elise C Kohn; Richard Piekarz; Kimberly K Leslie
Journal:  Clin Cancer Res       Date:  2021-03-25       Impact factor: 12.531

4.  Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.

Authors:  Yunn-Yi Chen; Sandy DeVries; Joseph Anderson; Juan Lessing; Rebecca Swain; Koei Chin; Veronica Shim; Laura J Esserman; Frederic M Waldman; E Shelley Hwang
Journal:  BMC Cancer       Date:  2009-08-18       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.